Ashish M. Kamat is a Professor of Urology and Wayne B. Duddlesten Professor of Cancer Research at M.D. Anderson Cancer Centre in Houston, TX. Dr. Kamat is also the Associate Head of the Cancer Centre, Reliance Foundation Hospital in Mumbai, served as the Director of the MD Anderson Urologic Oncology Fellowship from 2005-2016 and is a graduate of the AUA Leadership Program, 2008.


Dr. Kamat is recognized internationally as an expert in urologic oncology with an emphasis on bladder cancer, immunotherapy, organ-sparing and minimally invasive techniques. Dr. Kamat maintains an active research portfolio in this area with a focus on efforts to develop novel therapies, and identifying predictors of response to therapy (e.g. intravesical immunotherapy), as a first step towards personalized cancer therapeutics. He has initiated, led, and been active in several large studies including multinational trials in bladder cancer; these findings have been published in high impact journals and he is a co-PI on the MD Anderson GU SPORE (Bladder). Dr. Kamat is an exceptional educator and as Program Director grew the Urologic Oncology Fellowship into the premier program in the US and been nominated twice for the Robert M. Chamberlain Distinguished Mentor Award.


Dr. Kamat has authored numerous editorials, book chapters, and over 225 publications in peer reviewed journals, and serves on the editorial board of high ranked journals. He is listed in 'Who's Who in Medicine' and ‘Best Doctors in America’ and has won the ‘Compassionate Doctor Award’ from patient groups. He is recognized internationally for his efforts and has been invited as a visiting professor to several universities in the US and elsewhere; to deliver invited plenary sessions nationally (AUA); and internationally (eg. EAU, JUA, SIU, USI); to chair related committees eg: Society of Immunotherapy for Cancer (SITC); and as an AUA International Faculty. He is a member of the AUA Guidelines Panel for Bladder Cancer.


Dr. Kamat is President of the International Bladder Cancer Group (IBCG), Co-President of the International Bladder Cancer Network (IBCN), Chaired the Bladder Cancer Think Tank, actively participates in various Global urologic efforts (eg in setting up cancer centres overseas), serves on the board of regional and national societies for Urology (SCS AUA, Texas Urologic Society) & Urologic Oncology (SUO – CTC) and also in patient advocacy groups (MD Anderson Bladder Support Group, Bladder Cancer Advocacy Network, etc).


He lives in Houston, Texas with his wife and 2 children.